Navigation Links
Rhythm Names Keith M. Gottesdiener Chief Executive Officer
Date:11/9/2011

BOSTON, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today the appointment of Keith M. Gottesdiener, MD, as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from Merck & Co., Inc., where he served as Vice President and Late-Stage Therapeutic Group Leader, with responsibility for pivotal trials of Merck's products in all therapeutic areas, and previously as head of early-stage clinical development programs.

"The Rhythm clinical candidates are peptides with some important advantages over small molecules for targeting complex pathways that regulate body weight and gastrointestinal function," said Dr. Gottesdiener. "I am excited to join the Rhythm team to develop this pipeline of peptide therapeutics that have real potential to become breakthrough drugs for obesity, diabetes, and GI metabolic disorders."

Over a 16-year career at Merck, Dr. Gottesdiener was responsible for more than 40 major clinical programs and products, including the approval of Gardasil™ (HPV vaccine) and the more recent FDA approval of Victrelis™ (HCV protease inhibitor). Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania, and he completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs.

"Keith's experience and accomplishments developing innovative, best-in-class drugs—including the diabetes blockbuster, Januvia™—are exceptional," said Bart Henderson, President and co-founder of Rhythm. "He comes to Rhythm at an ideal time, as we advance clinical development of RM-131 for the treatment of diabetic gastroparesis and RM-493 for obesity and diabetes."

"Keith's deep understanding of the clinical development process will greatly enhance Rhythm's novel approach to molecular mechanisms of body weight regulation," said Lou Tartaglia, Ph.D., Rhythm's Chief Scientific Officer and a Partner at Third Rock Ventures. "We are very excited to have attracted such world-class talent to join us in building a great company in the metabolic field."

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Differing structures underlie differing brain rhythms in healthy and ill
2. Dangerous arrhythmia analyzed in a heartbeat
3. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
4. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
5. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
6. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
7. Guam rhino beetles got rhythm
8. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. OXIS International Names David Saloff as Chief Executive Officer
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the opening ... manage the new site. , Tim has 25 years of pharmaceutical experience, including ... as the Director of Manufacturing and Supplier Quality Assessment. This group is ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its ... someone who suffers from hay fever, urticaria, asthma, atopic eczema or a food ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy Regulation” ... perspectives by leading experts on the unique regulatory challenges of stem cell medical ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line ... until the first data on cross-contamination of human cell lines with HeLa cells were ... issue in cell culture labs and is associated with dramatic consequences for research. ...
Breaking Biology Technology:
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/20/2017)... ALLENTOWN, Pa. , March 20, 2017 ... PD 2.0 personal spirometer and Wellness Management System (WMS), ... Founded in 2010, PMD Healthcare is a ... Company with a mission dedicated to creating innovative solutions ... of life. With that intent focus, PMD developed the ...
Breaking Biology News(10 mins):